Condition: Episodic Migraine · Sponsor: St. Olavs Hospital
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
This description comes directly from the study's public registry record.
Lise R Øie, Post.doc. · 0047 41419596 · lise.r.oie@ntnu.no
Joakim H Østhus, Cand.med. · 0047 93837036 · Joakim.h.osthus@ntnu.no
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital | Bergen, Norway | Recruiting |
| University Hospital, Akershus | Lørenskog, Norway | Not Yet Recruiting |
| Oslo University Hospital, Rikshospitalet | Oslo, Norway | Not Yet Recruiting |
| Oslo University Hospital, Ullevål | Oslo, Norway | Not Yet Recruiting |
| University Hospital Northern Norway | Tromsø, Norway | Recruiting |
| St. Olavs hospital | Trondheim, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06248671